AU769035B2 - Detection of neoplasia by analysis of saliva - Google Patents
Detection of neoplasia by analysis of saliva Download PDFInfo
- Publication number
- AU769035B2 AU769035B2 AU29969/99A AU2996999A AU769035B2 AU 769035 B2 AU769035 B2 AU 769035B2 AU 29969/99 A AU29969/99 A AU 29969/99A AU 2996999 A AU2996999 A AU 2996999A AU 769035 B2 AU769035 B2 AU 769035B2
- Authority
- AU
- Australia
- Prior art keywords
- seq
- nucleic acid
- linear
- base pairs
- length
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 79
- 210000003296 saliva Anatomy 0.000 title claims abstract description 50
- 238000001514 detection method Methods 0.000 title claims abstract description 30
- 238000004458 analytical method Methods 0.000 title abstract description 18
- 230000009826 neoplastic cell growth Effects 0.000 title description 13
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 306
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 291
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 291
- 238000000034 method Methods 0.000 claims abstract description 85
- 201000011510 cancer Diseases 0.000 claims abstract description 30
- 210000004072 lung Anatomy 0.000 claims abstract description 14
- 239000002773 nucleotide Substances 0.000 claims description 68
- 125000003729 nucleotide group Chemical group 0.000 claims description 67
- 230000035772 mutation Effects 0.000 claims description 61
- 239000000523 sample Substances 0.000 claims description 55
- 238000009396 hybridization Methods 0.000 claims description 34
- 230000000295 complement effect Effects 0.000 claims description 31
- 230000003321 amplification Effects 0.000 claims description 28
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 28
- 108091034117 Oligonucleotide Proteins 0.000 claims description 16
- 108700020796 Oncogene Proteins 0.000 claims description 13
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 9
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 101710113436 GTPase KRas Proteins 0.000 claims description 7
- 238000012217 deletion Methods 0.000 claims description 7
- 230000037430 deletion Effects 0.000 claims description 7
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 4
- 230000000052 comparative effect Effects 0.000 claims 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 108010014186 ras Proteins Proteins 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 230000001613 neoplastic effect Effects 0.000 abstract description 13
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 231
- 239000013615 primer Substances 0.000 description 48
- 108091028043 Nucleic acid sequence Proteins 0.000 description 33
- 108091092878 Microsatellite Proteins 0.000 description 31
- 239000003795 chemical substances by application Substances 0.000 description 28
- 210000000349 chromosome Anatomy 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000003752 polymerase chain reaction Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- 230000002068 genetic effect Effects 0.000 description 15
- 230000002285 radioactive effect Effects 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 108700028369 Alleles Proteins 0.000 description 11
- 239000003155 DNA primer Substances 0.000 description 11
- 238000006116 polymerization reaction Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 210000003128 head Anatomy 0.000 description 9
- 230000004075 alteration Effects 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 102000043276 Oncogene Human genes 0.000 description 7
- 108700020978 Proto-Oncogene Proteins 0.000 description 7
- 102000052575 Proto-Oncogene Human genes 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000002759 chromosomal effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 208000014829 head and neck neoplasm Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 201000010536 head and neck cancer Diseases 0.000 description 6
- 210000003739 neck Anatomy 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 206010069754 Acquired gene mutation Diseases 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 230000002934 lysing effect Effects 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 230000037439 somatic mutation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- 230000004543 DNA replication Effects 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 230000000869 mutational effect Effects 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- -1 nucleoside triphosphates Chemical class 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000001226 triphosphate Substances 0.000 description 4
- 235000011178 triphosphate Nutrition 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 208000032818 Microsatellite Instability Diseases 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 231100000707 mutagenic chemical Toxicity 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 206010061764 Chromosomal deletion Diseases 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 201000008163 Dentatorubral pallidoluysian atrophy Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108091092919 Minisatellite Proteins 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 102000001218 Rec A Recombinases Human genes 0.000 description 2
- 108010055016 Rec A Recombinases Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108700025695 Suppressor Genes Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108700021042 biotin binding protein Proteins 0.000 description 2
- 102000043871 biotin binding protein Human genes 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000037434 nonsense mutation Effects 0.000 description 2
- 210000003300 oropharynx Anatomy 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000037432 silent mutation Effects 0.000 description 2
- 208000007183 sinonasal undifferentiated carcinoma Diseases 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- BAAVRTJSLCSMNM-CMOCDZPBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]pentanedioic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 BAAVRTJSLCSMNM-CMOCDZPBSA-N 0.000 description 1
- FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 description 1
- BCOSEZGCLGPUSL-UHFFFAOYSA-N 2,3,3-trichloroprop-2-enoyl chloride Chemical compound ClC(Cl)=C(Cl)C(Cl)=O BCOSEZGCLGPUSL-UHFFFAOYSA-N 0.000 description 1
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical class C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 1
- VUFNLQXQSDUXKB-DOFZRALJSA-N 2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 VUFNLQXQSDUXKB-DOFZRALJSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 102100021277 Beta-secretase 2 Human genes 0.000 description 1
- 101710150190 Beta-secretase 2 Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical group OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 101100335894 Caenorhabditis elegans gly-8 gene Proteins 0.000 description 1
- 101100459438 Caenorhabditis elegans nac-1 gene Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 241001123946 Gaga Species 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 description 1
- 101001001272 Homo sapiens Prostatic acid phosphatase Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000035346 Margins of Excision Diseases 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 1
- 102100029812 Protein S100-A12 Human genes 0.000 description 1
- 101710110949 Protein S100-A12 Proteins 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- SWPYNTWPIAZGLT-UHFFFAOYSA-N [amino(ethoxy)phosphanyl]oxyethane Chemical class CCOP(N)OCC SWPYNTWPIAZGLT-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VUSHQLWDOJFSGF-UHFFFAOYSA-L disodium 3-carboxy-3,5-dihydroxy-5-oxopentanoate chloride Chemical compound [Na+].[Na+].Cl.[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O VUSHQLWDOJFSGF-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000009841 epithelial lesion Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 208000032099 esthesioneuroblastoma Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004393 laryngeal mucosa Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 201000006385 lung benign neoplasm Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 102000053632 repetitive DNA sequence Human genes 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 108010032276 tyrosyl-glutamyl-tyrosyl-glutamic acid Proteins 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
- A61B10/0051—Devices for taking samples of body liquids for taking saliva or sputum samples
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003266475A AU2003266475B2 (en) | 1998-03-10 | 2003-12-04 | Detection of neoplasia by analysis of saliva |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/038,637 US6235470B1 (en) | 1993-11-12 | 1998-03-10 | Detection of neoplasia by analysis of saliva |
| US09/038637 | 1998-03-10 | ||
| PCT/US1999/005220 WO1999046408A1 (en) | 1998-03-10 | 1999-03-10 | Detection of neoplasia by analysis of saliva |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003266475A Division AU2003266475B2 (en) | 1998-03-10 | 2003-12-04 | Detection of neoplasia by analysis of saliva |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2996999A AU2996999A (en) | 1999-09-27 |
| AU769035B2 true AU769035B2 (en) | 2004-01-15 |
Family
ID=21901047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU29969/99A Expired AU769035B2 (en) | 1998-03-10 | 1999-03-10 | Detection of neoplasia by analysis of saliva |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US6235470B1 (enExample) |
| EP (1) | EP1062366B1 (enExample) |
| JP (2) | JP2002505888A (enExample) |
| AT (1) | ATE433498T1 (enExample) |
| AU (1) | AU769035B2 (enExample) |
| CA (1) | CA2323060A1 (enExample) |
| DE (1) | DE69940969D1 (enExample) |
| NO (1) | NO20004504L (enExample) |
| WO (1) | WO1999046408A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235470B1 (en) * | 1993-11-12 | 2001-05-22 | The Johns Hopkins University School Of Medicine | Detection of neoplasia by analysis of saliva |
| US6291163B1 (en) * | 1996-08-28 | 2001-09-18 | The Johns Hopkins University School Of Medicine | Method for detecting cell proliferative disorders |
| WO2003057918A1 (en) * | 2001-12-14 | 2003-07-17 | Zila, Inc | Light-directed molecular analysis for cancer prognosis and diagnosis |
| US7888324B2 (en) * | 2001-08-01 | 2011-02-15 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| US7407943B2 (en) * | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US20060009410A1 (en) * | 2002-11-13 | 2006-01-12 | Crooke Rosanne M | Effects of apolipoprotein B inhibition on gene expression profiles in animals |
| US7511131B2 (en) * | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| JP5686493B2 (ja) | 2003-01-24 | 2015-03-18 | ユニバーシティ・オブ・ユタＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｕｔａｈ | テロメアの長さを決定することによって死亡の危険性を予測する方法 |
| EP1730160A4 (en) * | 2004-03-17 | 2008-04-09 | Univ Johns Hopkins | Neoplasia diagnostic compositions and methods of use |
| US20050287558A1 (en) | 2004-05-05 | 2005-12-29 | Crooke Rosanne M | SNPs of apolipoprotein B and modulation of their expression |
| DK2997980T3 (en) * | 2004-08-10 | 2018-03-26 | Kastle Therapeutics Llc | PROCEDURES FOR MODULATING LIPROPROTEIN AND CHOLESTEROL LEVELS |
| JP5731115B2 (ja) | 2006-05-05 | 2015-06-10 | アイシス ファーマシューティカルズ， インコーポレーテッド | 遺伝子発現を調節するための化合物および方法 |
| AU2007249805B2 (en) * | 2006-05-12 | 2013-01-10 | University Of Miami | Biomarkers for detection and diagnosis of head and neck squamous cell carcinoma |
| KR20090128494A (ko) * | 2007-03-24 | 2009-12-15 | 겐자임 코포레이션 | 인간 아포리포프로틴 ｂ에 상보적인 안티센스 올리고뉴클레오타이드 투여 |
| US20090023138A1 (en) * | 2007-07-17 | 2009-01-22 | Zila Biotechnology, Inc. | Oral cancer markers and their detection |
| US8012678B2 (en) * | 2007-07-24 | 2011-09-06 | Wisconsin Alumni Research Foundation | Biomarkers for human papilloma virus-associated cancer |
| CN102439171B (zh) | 2008-12-22 | 2017-07-14 | 犹他大学研究基金会 | 单色多重定量pcr |
| EP2408796B1 (en) | 2009-03-16 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III |
| ITBO20090554A1 (it) * | 2009-08-27 | 2011-02-28 | Maria Gabriella Fornaro | Metodo per individuare la predisposizione al carcinoma della prostata. |
| ES2633111T3 (es) * | 2010-03-26 | 2017-09-19 | Hongzhi Zou | Métodos y materiales para detectar neoplasia colorrectal |
| JP6174035B2 (ja) | 2011-11-15 | 2017-08-02 | ユニヴァーシティ・オヴ・マイアミ | ヒトパピローマウイルスを検出し頭頸部扁平上皮癌を予後予測する方法 |
| TW201343919A (zh) * | 2011-12-31 | 2013-11-01 | Telome Health Inc | 唾液衍生之端粒豐度計量及樣本收集裝置 |
| US9506116B2 (en) | 2013-03-14 | 2016-11-29 | Mayo Foundation For Medical Education And Research | Detecting neoplasm |
| HK1220737A1 (zh) | 2013-05-22 | 2017-05-12 | Telomere Diagnostics, Inc. | 短端粒丰度的量度 |
| WO2015153284A1 (en) | 2014-03-31 | 2015-10-08 | Mayo Foundation For Medical Education And Research | Detecting colorectal neoplasm |
| US10184154B2 (en) | 2014-09-26 | 2019-01-22 | Mayo Foundation For Medical Education And Research | Detecting cholangiocarcinoma |
| CA2971169A1 (en) | 2014-12-30 | 2016-07-07 | Telomere Diagnostics, Inc. | Multiplex quantitative pcr |
| US10030272B2 (en) | 2015-02-27 | 2018-07-24 | Mayo Foundation For Medical Education And Research | Detecting gastrointestinal neoplasms |
| CN107532124B (zh) | 2015-03-27 | 2022-08-09 | 精密科学公司 | 检测食管疾病 |
| CN108138235B (zh) | 2015-08-31 | 2022-04-15 | 梅约医药教育及研究基金会 | 检测胃肿瘤 |
| US10370726B2 (en) | 2016-04-14 | 2019-08-06 | Mayo Foundation For Medical Education And Research | Detecting colorectal neoplasia |
| AU2017250663B2 (en) | 2016-04-14 | 2023-06-15 | Mayo Foundation For Medical Education And Research | Detecting pancreatic high-grade dysplasia |
| KR102747156B1 (ko) | 2017-02-28 | 2024-12-26 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 전립선 암의 검출 |
| CA3084584A1 (en) | 2017-11-30 | 2019-06-06 | Mayo Foundation For Medical Education And Research | Detecting breast cancer |
| TW202015719A (zh) | 2018-06-19 | 2020-05-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| CN114885938A (zh) * | 2022-02-25 | 2022-08-12 | 厦门迈威生物科技有限公司 | 一种浆膜腔积液脱落细胞保存液及其生产方法 |
| USD1034632S1 (en) * | 2022-05-03 | 2024-07-09 | SimpliSafe, Inc. | Display screen with graphical user interface |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996006951A1 (en) * | 1994-08-31 | 1996-03-07 | The Johns Hopkins University School Of Medicine | Detection of hypermutable nucleic acid sequence in tissue |
| US5561041A (en) * | 1993-11-12 | 1996-10-01 | The Johns Hopkins University School Of Medicine | Nucleic acid mutation detection by analysis of sputum |
| WO1998008980A1 (en) * | 1996-08-28 | 1998-03-05 | The Johns Hopkins University School Of Medicine | Method for detecting cell proliferative disorders |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5527676A (en) | 1989-03-29 | 1996-06-18 | The Johns Hopkins University | Detection of loss of the wild-type P53 gene and kits therefor |
| DE69032864T3 (de) | 1989-03-29 | 2013-01-31 | The Johns Hopkins University | Nachweis des Ausfalls des Wildtyps des p53-Gens |
| WO1992000311A1 (en) | 1990-06-27 | 1992-01-09 | Princeton University | Probes for detecting mutant p53 |
| AU662906B2 (en) | 1991-06-26 | 1995-09-21 | F. Hoffmann-La Roche Ag | Methods for detection of carcinoma metastases by nucleic acid amplification |
| ATE253645T1 (de) | 1992-04-01 | 2003-11-15 | Univ Johns Hopkins Med | Verfahren zur bestimmung von säugetier nukleinsäuren aus stuhlproben und dafür benötigte reagenzien |
| JP2001507921A (ja) | 1992-04-27 | 2001-06-19 | トラスティーズ オブ ダートマス カレッジ | 生物学的液体中の遺伝子配列の検出 |
| US6235470B1 (en) * | 1993-11-12 | 2001-05-22 | The Johns Hopkins University School Of Medicine | Detection of neoplasia by analysis of saliva |
| CH686982A5 (fr) * | 1993-12-16 | 1996-08-15 | Maurice Stroun | Méthode pour le diagnostic de cancers. |
| US5589579A (en) | 1994-07-19 | 1996-12-31 | Cytoclonal Pharmaceutics, Inc. | Gene sequence and probe for a marker of non-small cell lung carinoma |
| DE19712332A1 (de) * | 1997-03-25 | 1998-10-01 | Boehringer Mannheim Gmbh | Verfahren zum Nachweis von Mikrosatelliten-Instabilität zur Tumordiagnostik |
| WO1998044158A1 (en) * | 1997-03-28 | 1998-10-08 | Epitope, Inc. | Simultaneous collection of dna and non-nucleic analytes from oral fluids |
-
1998
- 1998-03-10 US US09/038,637 patent/US6235470B1/en not_active Expired - Lifetime
-
1999
- 1999-03-10 DE DE69940969T patent/DE69940969D1/de not_active Expired - Lifetime
- 1999-03-10 WO PCT/US1999/005220 patent/WO1999046408A1/en not_active Ceased
- 1999-03-10 EP EP99911289A patent/EP1062366B1/en not_active Expired - Lifetime
- 1999-03-10 AU AU29969/99A patent/AU769035B2/en not_active Expired
- 1999-03-10 JP JP2000535774A patent/JP2002505888A/ja active Pending
- 1999-03-10 AT AT99911289T patent/ATE433498T1/de not_active IP Right Cessation
- 1999-03-10 CA CA002323060A patent/CA2323060A1/en not_active Abandoned
-
2000
- 2000-09-08 NO NO20004504A patent/NO20004504L/no unknown
-
2001
- 2001-05-22 US US09/863,806 patent/US20020197608A1/en not_active Abandoned
-
2004
- 2004-01-05 JP JP2004000679A patent/JP2004159661A/ja active Pending
- 2004-01-09 US US10/754,478 patent/US7279312B2/en not_active Expired - Fee Related
-
2007
- 2007-10-08 US US11/868,683 patent/US7601521B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5561041A (en) * | 1993-11-12 | 1996-10-01 | The Johns Hopkins University School Of Medicine | Nucleic acid mutation detection by analysis of sputum |
| WO1996006951A1 (en) * | 1994-08-31 | 1996-03-07 | The Johns Hopkins University School Of Medicine | Detection of hypermutable nucleic acid sequence in tissue |
| WO1998008980A1 (en) * | 1996-08-28 | 1998-03-05 | The Johns Hopkins University School Of Medicine | Method for detecting cell proliferative disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| US6235470B1 (en) | 2001-05-22 |
| ATE433498T1 (de) | 2009-06-15 |
| US7279312B2 (en) | 2007-10-09 |
| HK1033765A1 (en) | 2001-09-21 |
| AU2003266475A1 (en) | 2004-01-22 |
| US20020197608A1 (en) | 2002-12-26 |
| US20080124729A1 (en) | 2008-05-29 |
| EP1062366A1 (en) | 2000-12-27 |
| NO20004504L (no) | 2000-11-08 |
| AU2996999A (en) | 1999-09-27 |
| US20050009040A1 (en) | 2005-01-13 |
| CA2323060A1 (en) | 1999-09-16 |
| EP1062366A4 (en) | 2002-05-08 |
| EP1062366B1 (en) | 2009-06-10 |
| WO1999046408A1 (en) | 1999-09-16 |
| JP2004159661A (ja) | 2004-06-10 |
| DE69940969D1 (de) | 2009-07-23 |
| US7601521B2 (en) | 2009-10-13 |
| NO20004504D0 (no) | 2000-09-08 |
| JP2002505888A (ja) | 2002-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU769035B2 (en) | Detection of neoplasia by analysis of saliva | |
| US6177251B1 (en) | Method for detection of target nucleic acid by analysis of stool | |
| US6479234B1 (en) | Detection of hypermutable nucleic acid sequence in tissue and body fluids | |
| Blanquet et al. | Spectrum of germline mutations in the RB1 gene: a study of 232 patients with hereditary and non hereditary retinoblastoma | |
| US20130149695A1 (en) | Method for detecting genetic mutation by using a blocking primer | |
| WO1996006951A9 (en) | Detection of hypermutable nucleic acid sequence in tissue | |
| JPH11504809A (ja) | 精神分裂症の診断方法 | |
| JP2002533054A (ja) | Ｂｒｃａ２の癌罹患性突然変異 | |
| US6063567A (en) | Method, reagents and kit for diagnosis and targeted screening for retinoblastoma | |
| HK1033765B (en) | Detection of neoplasia by analysis of saliva | |
| US7611841B2 (en) | Method for detecting methylation of promoter using restriction enzyme and DNA chip | |
| Cotter | The role of polymerase chain reaction in pathology | |
| CN119351552A (zh) | 用于检测肺癌的组合物及其用途 | |
| MXPA97001549A (en) | Detection of sequences of nucleic acids, hydrochlortable in teji |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |